1 / 8

Blocviroc – an innovative treatment for HIV/AIDS

Blocviroc – an innovative treatment for HIV/AIDS. Steve English Development Head, Antivirals. The Context. HIV/AIDs is the world’s greatest threat to human health Over 40 million people are infected worldwide

christmas
Download Presentation

Blocviroc – an innovative treatment for HIV/AIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Blocviroc – an innovative treatment for HIV/AIDS Steve EnglishDevelopment Head, Antivirals

  2. The Context • HIV/AIDs is the world’s greatest threat to human health • Over 40 million people are infected worldwide • There is no known cure. Treatments have improved but there are still problems with virus resistance and patient adherence • Blocviroc is a novel treatment and patients would take one pill per day

  3. Mode of Action • Blocviroc treats the host rather than attacking the virus • It binds to two receptors on the surface of human immune cells known as T-cells • It prevents the virus entering the cell • Blocviroc is more effective than existing therapies

  4. HIV CD4 CCR5 CCR5 antagonist Human immune cell surface

  5. Phase II Trials • Excellent results. • In just two weeks viral count dropped by 90% in volunteer patients • Only minor side effects • On stopping treatment, the viral count did not rise immediately

  6. Phase III Trials • Expensive – around $500 million • 5,000 volunteers needed from all around the world • Three year study • Risks: • Similar compounds have caused liver damage • Not sure of the long-term effect of interfering with the immune system • A competitor might discover a vaccine

  7. Market Considerations • Not going to be a blockbuster • Over 2 million people in Europe and North America have AIDS • A treatment not a cure – patients will have to continue with the drug • Manufacturing Blocviroc will be expensive • Regulators will look favourably on a new treatment for HIV

  8. Questions

More Related